AzTrials
AzTrials

Rheumatoid ArthritisPhase 4NCT01010503

A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.

A Phase 4 study testing tocilizumab [RoActemra/Actemra] in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 1 site in Slovakia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to non-biologic DMARDs. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
tocilizumab [RoActemra/Actemra]
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
1 siteSlovakia
Study dates
Jun 2009to May 2010
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • adult patients >/= 18 years of age
  • moderate to severe active rheumatoid arthritis
  • inadequate response, or intolerance to previous therapy with one or more traditional DMARDs
  • DAS >3.6
  • pneumology examination (including chest x-ray and quantiferon)

Who cannot join

  • < 18 years of age
  • active infection
  • active tuberculosis
  • uncontrolled hyperlipoproteinaemia
  • demyelinating disorders
  • concomitant anti-TNF drugs
  • history of intestinal ulceration and diverticulitis

Trial locations and contacts

1 site in 1 country.

Slovakia1 site
  • Study site

    Piešťany, 921 12

Other trials in Slovakia

About this study

Official title: Evaluation of Adherence and Persistence to Tocilizumab in Combination With Methotrexate or Tocilizumab Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis in Local Environment.

This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to non-biologic DMARDs. Patients will receive tocilizumab 8 mg/kg as intravenous infusion once every 4 weeks in combination with methotrexate or in case of intolerance to methotrexate as monotherapy. The anticipated time of study treatment is 6 months. The target sample size is 20-50 patients.

Being tested
tocilizumab [RoActemra/Actemra]
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tocilizumab [RoActemra/Actemra]Drug

    tocilizumab 8 mg/kg intravenous infusion once in 4 weeks

Study groups in NCT01010503
Study groupRoleWhat they receive
Single ArmExperimentalNot described
Receives: Drug: tocilizumab [RoActemra/Actemra]

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Adherent to Original Treatment

    Adherence rate to original treatment according to the protocol included all participants that received the study drug beginning from Week 8 and remaining until the end of the study. This number represents participants with no changes in treatment protocol, participants with treatment discontinuation, and participants with dose reduction, but not participants that withdrew from the study prematurely.

    Measured: Week 24

  2. Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  3. Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  4. Percentage of Participants Withdrawing From the Study Prematurely for Any Reason

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  5. Percentage of Participants With Dose Reduction to Tocilizumab 4 mg/kg

    Measured: Weeks 0, 4, 8, 12, 16, and 20

Secondary outcomes (10)
  1. Disease Activity Score Based on 28-Joint Count (DAS28)

    DAS28 calculated from the number of swollen joints and tender joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.

    Measured: Weeks 0, 4, 12, and 24

  2. Patient Global Assessment of Pain

    Participants were asked to rate their pain using a 0 to 100 mm visual analog scale (VAS), where 0 mm = no pain and 100 mm = worst possible pain. The participant was asked to mark the line corresponding to their perceived level of pain and the distance in mm from the left edge of the scale was measured.

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  3. Patient Global Assessment of Disease Activity

    The participant's assessment of disease activity was performed using a 100 mm VAS ranging from no activity (0) to maximal activity (100). The participant was asked to mark the line corresponding to their perceived level of disease activity and the distance in mm from the left edge of the scale was measured.

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  4. Physician's Global Assessment of Disease Activity

    Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The physician was asked to mark the line corresponding to their perceived level of the participant's disease activity and the distance in mm from the left edge of the scale was measured.

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  5. Swollen Joint Count (SJC)

    The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not swollen or 1=swollen. The total number was calculated from all the joints for a maximum score of 28.

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  6. Tender Joint Count (TJC)

    The following 28 joints were assessed by the physician for tenderness: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not tender or 1=tender. The total number was calculated from all the joints for a maximum score of 28.

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  7. Erythrocyte Sedimentation Rate (ESR)

    ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.

    Measured: Weeks 0, 4, 12, 20, and 24

  8. C-Reactive Protein (CRP)

    CRP is an acute phase protein. Levels of CRP increase with inflammation.

    Measured: Weeks 0, 4, 12, 20, and 24

  9. Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.

    Measured: Weeks 0, 4, 8, 12, 16, 20, and 24

  10. Short Form-36 (SF-36)

    The SF-36 measures the impact of disease on overall quality of life and consists of 8 subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health.

    Measured: Weeks 0, 12, and 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Nov 2009 (estimated)
  2. Study startJun 2009
  3. Primary completionMay 2010
  4. Study completionMay 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01010503
Sponsor's protocol ID
ML22508
Other IDs
2009-011520-53, 2009
Status last verified
Jul 2014
First submitted
9 Nov 2009
Last updated
13 Aug 2014

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing tocilizumab [RoActemra/Actemra] in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 1 site in Slovakia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Aug 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Slovakia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Aug 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Adherent to Original Treatment (time frame: Week 24). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in